论文部分内容阅读
科学家都在“摸爬滚打”中磕磕绊绊走到了今天。如今,埃博拉又再次抛出了新的难题:如何设计临床试验?新事物的发展总是曲折前进的。从今年2月埃博拉西非疫情暴发,到11月12日世界卫生组织(WHO)表示,埃博拉病毒造成的死亡人数已经超过5000人,感染病例达1.4万多个。这一路走来,不仅疫区的人诚惶诚恐,科学家同样步步惊心。不论是最初的试验性药物供不应求,还是“重新目的化”药物引发道德争议,又或是疫苗研制屡陷困境,科学家都在“摸爬滚打”中磕磕绊绊走到了今天。
Scientists are stumbling in “fumble” in today’s. Now, Ebola again throws new challenges: how to design clinical trials? The development of new things is always twists and turns. From the outbreak of the Ebola outbreak in West Africa in February this year to November 12, the World Health Organization (WHO) said that the number of deaths caused by the Ebola virus has exceeded 5,000 and the number of infections reached more than 14,000. Along the way, not only people in the affected areas are in a state of trepidation and fear, scientists are equally alarmed. Whether it is the initial trial of drug shortage, or “re-purposive” drug-induced ethical controversy, or vaccine development in troubled times, scientists are stumbling in the “fumble” in today’s stumbling.